Fluorodeoxyglucose Positron Emission Tomography and the Prognosis of Pancreatic Carcinoma

Pancreatic carcinoma is associated with a poor prognosis. The aim of this study was to determine whether glucose metabolism in pancreatic cancer has prognostic significance for patients suffering from this disease. The survival data of 52 patients with pancreatic carcinoma was correlated with the st...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of gastroenterology 2000, Vol.35 (8), p.883-888
Main Authors: ZIMNY, M, FASS, J, BARES, R, CREMERIUS, U, SABRI, O, BUECHIN, P, SCHUMPELICK, V, BUELL, U
Format: Article
Language:English
Subjects:
Adenocarcinoma - diagnostic imaging
Adenocarcinoma - mortality
Aged
Analysis of Variance
Biological and medical sciences
Digestion. Liver. Biliary tract. Spleen. Pancreas
Female
Fluorodeoxyglucose F18
Humans
Investigative techniques, diagnostic techniques (general aspects)
Male
Medical sciences
Middle Aged
Multivariate Analysis
Pancreatic Neoplasms - diagnostic imaging
Pancreatic Neoplasms - mortality
Probability
Prognosis
Radionuclide investigations
Sensitivity and Specificity
Severity of Illness Index
Survival Rate
Tomography, Emission-Computed
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic carcinoma is associated with a poor prognosis. The aim of this study was to determine whether glucose metabolism in pancreatic cancer has prognostic significance for patients suffering from this disease. The survival data of 52 patients with pancreatic carcinoma was correlated with the standardized uptake value (SUV) as a semiquantitative parameter of glucose metabolism, as determined with fluorodeoxyglucose positron emission tomography (FDG PET). A multivariate analysis, including SUV and accepted factors of prognosis, such as stage at presentation and tumor marker Ca 19-9, was performed to determine the prognostic value of FDG PET. The median survival in 26 patients with low SUV (< 6.1) was 9 months (95% confidence interval 6-12 months) vs. 5 months (95% confidence interval 4-6 months) in 26 patients with high SUV (> or = 6.1). Multivariate analysis revealed SUV and tumor marker Ca 19-9 as independent factors of prognosis in patients with pancreatic carcinoma. Glucose metabolism, as determined with FDG PET, provides additional prognostic information in patients with pancreatic carcinoma.
ISSN:0036-5521
1502-7708
DOI:10.1080/003655200750023273